An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease
- 4 July 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 17 (13) , 1745-1756
Abstract
Introduction: The lack of a complete understanding of the complex processes involved in the etiopathogenesis and subsequent appropriate phenotyping makes it difficult to find therapies that may be efficacious in most patients with osteoarthritis (OA). Consensus recommendations involve mainly non-pharmacological approaches. Analgesics and NSAIDs are considered second choice options due to their poor efficacy/safety ratios. To some extent, OA may be considered an orphan disease. Therefore, there is an urgent need to identify effective and safe new pharmacologic modalities for treating OA. Areas covered: This review is based on a Medline comprehensive literature search for published articles evaluating new formulations of current drugs and promising emerging therapies in OA. We discuss the current status of novel systemic agents in development including potent analgesic options, inhibitors of innate immunity, inducible nitric oxide synthase (iNOS), pro-inflammatory cytokines and cartilage proteases as well as bone agents. Furthermore, we also revise the potential benefit of intraarticular (IA) therapy with hyaluronic acid (HA), pro-inflammatory mediator blockers, cartilage anabolic agents, mesenchymal stem cell and gene transfer. Expert opinion: Despite the renewed interest in the search of new compounds for treatment of OA, results have been limited. Novel systemic and IA administered agents are in active development. IA drug administration is particularly an attractive approach because can diminish some of the severe side effects associated with systemic drugs. Indeed, one of the most promising fields for pharmacology innovation in OA is joint injected therapy, as suggested by preliminary data from recent studies using IA sprifermin (rhFGF-18), mesenchymal stem cells or TGF-B1 transduced allogenic chondrocytes. Last, the effort to develop new drugs must be accompanied by the interest for establishing well-defined phenotypes, and only then, a more tailored therapy should be practiced in OA.Keywords
Funding Information
- Fondo de Investigación Sanitaria (PS09/01625 and PI12/00144)
This publication has 130 references indexed in Scilit:
- Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trialsThe Lancet, 2013
- American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and kneeArthritis Care & Research, 2012
- Biomechanical factors in osteoarthritisBest Practice & Research Clinical Rheumatology, 2011
- Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis – meta-analysisOsteoarthritis and Cartilage, 2011
- Interleukin‐6 is a significant predictor of radiographic knee osteoarthritis: The Chingford studyArthritis & Rheumatism, 2009
- Mitogen-activated protein kinases as therapeutic targets in osteoarthritisCurrent Opinion in Rheumatology, 2008
- Adenosine receptors: therapeutic aspects for inflammatory and immune diseasesNature Reviews Drug Discovery, 2008
- Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanasesThe FASEB Journal, 2008
- Molecular mechanisms of cartilage destruction: Mechanics, inflammatory mediators, and aging collideArthritis & Rheumatism, 2006
- The incidence and natural history of knee osteoarthritis in the elderly, the framingham osteoarthritis studyArthritis & Rheumatism, 1995